FDA Calendar

We update our data in realtime to provide you with the latest FDA Approvals and Trials for new Drugs and Studies from US Stock Companies.

Jan 23, 2025

Drug: Evorpacept

Description: ASPEN-06 trial. First person dosed 3/2/22. 10/3/23 Positive Interim Ph2 results. 7/31/24- Topline data & webcast. 8/8/24- Updated Ph2 data in H1 2025. Plan to initiate the Ph3 portion in mid-2025. 12/18/24- Present updated results at ASCO GI Cancers Symposium on January 23, 2025.

Indication: Cancer, Gastric cancer

Status: Phase 2

Company:

Drug: Vilastobart

Description: Phase 1/2 data presented at ASCO GI on January 23-25, 2025.

Indication: Microsatellite stable colorectal cancer (MSS CRC)

Status: Phase 1/2

Company:

Jan 24, 2025

Drug: Casdozokitug

Description: 1/18/24 Positive Ph2 data at ASCO GI '24.12/18/24- Present final Ph2 data at ASCO-GI '25.

Indication: Cancer, Hepatocellular carcinoma

Status: Phase 2

Company:

Trade Smarter, Not Harder

Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.

Unlimited access to all data and tools
Unlimited access to all data and tools, giving you the edge over everyone else in the market.
Realtime Options Data
Instant access to live options data to spot opportunities and trade with precision before the market moves.
Top Wallstreet Analyst Ratings
Follow ratings from the best analysts on Wall Street to stay ahead.
Up to 30 years financial history
We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.